Precision Therapeutics (AIPT) Earns Media Impact Score of 0.01
Media coverage about Precision Therapeutics (NASDAQ:AIPT) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Precision Therapeutics earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 42.334142394822 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Precision Therapeutics traded down $0.08, reaching $1.12, during midday trading on Thursday, MarketBeat.com reports. The company had a trading volume of 890 shares, compared to its average volume of 652,627. Precision Therapeutics has a 12-month low of $0.81 and a 12-month high of $2.50.
Precision Therapeutics (NASDAQ:AIPT) last posted its quarterly earnings results on Monday, April 2nd. The medical instruments supplier reported ($0.43) earnings per share for the quarter. Precision Therapeutics had a negative net margin of 915.36% and a negative return on equity of 244.46%. The business had revenue of $0.22 million during the quarter.
Precision Therapeutics Inc manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the United States. It also engages in the development of a healthcare contract research organization (CRO) that provides personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries.
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.